Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35902718)

  • 21. HER2 expression variability between primary gastric cancers and corresponding lymph node metastases.
    Qiu Z; Sun W; Zhou C; Zhang J
    Hepatogastroenterology; 2015; 62(137):231-3. PubMed ID: 25911901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides.
    Wei Q; Xu J; Shen L; Fu X; Zhang B; Zhou X; Carlsson J
    Tumour Biol; 2014 Jul; 35(7):6319-26. PubMed ID: 24643685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer.
    Zhang P; Ji DB; Han HB; Shi YF; Du CZ; Gu J
    World J Gastroenterol; 2014 Sep; 20(34):12241-8. PubMed ID: 25232258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients.
    Baroš IV; Tanasković N; Pellas U; Eri Ž; Tadić Latinović L; Tot T
    Bosn J Basic Med Sci; 2019 Aug; 19(3):242-248. PubMed ID: 30957723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].
    Liu YY; Wu SF; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):393-6. PubMed ID: 27256047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
    Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR expression variance in paired colorectal cancer primary and metastatic tumors.
    Yarom N; Marginean C; Moyana T; Gorn-Hondermann I; Birnboim HC; Marginean H; Auer RC; Vickers M; Asmis TR; Maroun J; Jonker D
    Cancer Biol Ther; 2010 Sep; 10(5):416-21. PubMed ID: 20595818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
    Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
    Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
    Ahmed AR
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.
    Saito T; Nakanishi H; Mochizuki Y; Ito S; Ito Y; Misawa K; Yatabe Y; Yamamichi K; Kondo E
    Gastric Cancer; 2015 Oct; 18(4):711-9. PubMed ID: 25173363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes.
    Seethala RR; Gooding WE; Handler PN; Collins B; Zhang Q; Siegfried JM; Grandis JR
    Clin Cancer Res; 2008 Mar; 14(5):1303-9. PubMed ID: 18316548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.